IDH1 and glioma: Moreover, mutations in IDH1 and IDH2, recurrently observed in gliomas and acute myeloid leukemias, lead to the neomorphic production of 2-hydroxyglutarate (2HG), a competitive inhibitor of αKG-dependent dioxygenases.